LIXTE Biotechnology Holdings Inc. has appointed Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary, a strategic move to advance the company's position in cancer radiotherapy. Braun, who previously facilitated LIXTE's acquisition of Liora's assets, brings more than 20 years of healthcare operational and strategic advisory experience to the role. He will lead advancement of Liora's LiGHT System, an electronically controlled proton therapy platform designed to enhance tumor treatment. Management stated the appointment supports its strategy to scale the technology and pursue a recurring revenue model within the radiotherapy segment of cancer care.
The move comes as LIXTE continues to advance its broader cancer treatment portfolio, which includes its first-in-class lead clinical PP2A inhibitor, LB-100. According to the company, LB-100 has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity and has the potential to significantly enhance chemotherapies and immunotherapies. LIXTE's approach represents a pioneering effort in an entirely new field of cancer biology called activation lethality, which is advancing a new treatment paradigm. The company's comprehensive patent portfolio covers this innovative approach. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer, with extensive preclinical data available through the company's website at https://www.lixte.com.
The appointment of Braun to lead the European subsidiary represents a strategic step in LIXTE's expansion within the cancer radiotherapy market. Proton therapy represents an advanced form of radiation treatment that uses protons rather than X-rays to treat cancer, potentially offering more precise targeting of tumors while sparing surrounding healthy tissue. The LiGHT System's electronically controlled platform could represent a significant advancement in this treatment modality. For investors seeking additional information about LIXTE's developments, the company maintains a newsroom at https://ibn.fm/LIXT where updates are regularly posted.
The broader biomedical community can access specialized communications through platforms like BioMedWire, which focuses on developments in biotechnology and life sciences sectors. More information about this communications platform is available at https://www.BioMedWire.com. The strategic appointment comes at a time when cancer treatment technologies are rapidly evolving, with companies seeking to develop more targeted and effective therapies. LIXTE's dual approach of advancing both pharmaceutical compounds like LB-100 and medical technology platforms like the LiGHT System positions the company across multiple segments of cancer care innovation. The company's focus on establishing a recurring revenue model within radiotherapy suggests a long-term strategy for sustainable growth in this specialized healthcare sector.
